nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—XDH—Doxorubicin—sarcoma	0.15	0.384	CbGbCtD
Trifluoperazine—CYP1A2—Dacarbazine—sarcoma	0.0587	0.15	CbGbCtD
Trifluoperazine—ABCB1—Dactinomycin—sarcoma	0.0445	0.114	CbGbCtD
Trifluoperazine—ABCB1—Mitoxantrone—sarcoma	0.0398	0.102	CbGbCtD
Trifluoperazine—CYP1A2—Etoposide—sarcoma	0.0287	0.0733	CbGbCtD
Trifluoperazine—ABCB1—Vincristine—sarcoma	0.0274	0.0699	CbGbCtD
Trifluoperazine—ABCB1—Etoposide—sarcoma	0.0251	0.0641	CbGbCtD
Trifluoperazine—ABCB1—Doxorubicin—sarcoma	0.0171	0.0437	CbGbCtD
Trifluoperazine—S100A4—myometrium—sarcoma	0.00475	0.0267	CbGeAlD
Trifluoperazine—HTR2A—pulmonary artery—sarcoma	0.00463	0.0261	CbGeAlD
Trifluoperazine—S100A4—embryo—sarcoma	0.00457	0.0257	CbGeAlD
Trifluoperazine—S100A4—seminal vesicle—sarcoma	0.00429	0.0242	CbGeAlD
Trifluoperazine—S100A4—hematopoietic system—sarcoma	0.00408	0.023	CbGeAlD
Trifluoperazine—S100A4—connective tissue—sarcoma	0.00393	0.0221	CbGeAlD
Trifluoperazine—EBP—uterus—sarcoma	0.00374	0.0211	CbGeAlD
Trifluoperazine—S100A4—smooth muscle tissue—sarcoma	0.00359	0.0202	CbGeAlD
Trifluoperazine—UGT1A4—hematopoietic system—sarcoma	0.00358	0.0202	CbGeAlD
Trifluoperazine—S100A4—skin of body—sarcoma	0.00355	0.02	CbGeAlD
Trifluoperazine—TNNC1—hematopoietic system—sarcoma	0.00343	0.0193	CbGeAlD
Trifluoperazine—TNNC1—connective tissue—sarcoma	0.00331	0.0186	CbGeAlD
Trifluoperazine—S100A4—cardiac atrium—sarcoma	0.0031	0.0174	CbGeAlD
Trifluoperazine—S100A4—uterus—sarcoma	0.00308	0.0173	CbGeAlD
Trifluoperazine—S100A4—lymphoid tissue—sarcoma	0.00287	0.0162	CbGeAlD
Trifluoperazine—EBPL—testis—sarcoma	0.00283	0.0159	CbGeAlD
Trifluoperazine—HTR2A—hindlimb—sarcoma	0.0028	0.0158	CbGeAlD
Trifluoperazine—S100A4—tendon—sarcoma	0.0027	0.0152	CbGeAlD
Trifluoperazine—EBPL—liver—sarcoma	0.00268	0.0151	CbGeAlD
Trifluoperazine—S100A4—bone marrow—sarcoma	0.00262	0.0147	CbGeAlD
Trifluoperazine—TNNC1—cardiac atrium—sarcoma	0.00261	0.0147	CbGeAlD
Trifluoperazine—CALY—testis—sarcoma	0.00259	0.0146	CbGeAlD
Trifluoperazine—EBP—liver—sarcoma	0.00257	0.0144	CbGeAlD
Trifluoperazine—CALM3—mammary gland—sarcoma	0.00245	0.0138	CbGeAlD
Trifluoperazine—HTR2A—appendage—sarcoma	0.0024	0.0135	CbGeAlD
Trifluoperazine—CALM2—endothelium—sarcoma	0.00239	0.0135	CbGeAlD
Trifluoperazine—CALM1—endothelium—sarcoma	0.00238	0.0134	CbGeAlD
Trifluoperazine—Ileus—Vincristine—sarcoma	0.00232	0.0138	CcSEcCtD
Trifluoperazine—TNNC1—tendon—sarcoma	0.00227	0.0128	CbGeAlD
Trifluoperazine—S100A4—testis—sarcoma	0.00224	0.0126	CbGeAlD
Trifluoperazine—Pigmentation disorder—Epirubicin—sarcoma	0.00224	0.0133	CcSEcCtD
Trifluoperazine—SIGMAR1—mammary gland—sarcoma	0.00219	0.0123	CbGeAlD
Trifluoperazine—S100A4—liver—sarcoma	0.00211	0.0119	CbGeAlD
Trifluoperazine—Amenorrhoea—Thiotepa—sarcoma	0.00211	0.0125	CcSEcCtD
Trifluoperazine—Pigmentation disorder—Doxorubicin—sarcoma	0.00207	0.0123	CcSEcCtD
Trifluoperazine—EBPL—lymph node—sarcoma	0.00205	0.0115	CbGeAlD
Trifluoperazine—CALM1—mammary gland—sarcoma	0.00192	0.0108	CbGeAlD
Trifluoperazine—TNNC1—testis—sarcoma	0.00188	0.0106	CbGeAlD
Trifluoperazine—CALY—lymph node—sarcoma	0.00188	0.0106	CbGeAlD
Trifluoperazine—UGT1A4—liver—sarcoma	0.00186	0.0104	CbGeAlD
Trifluoperazine—Amenorrhoea—Mitoxantrone—sarcoma	0.00182	0.0108	CcSEcCtD
Trifluoperazine—CALM3—myometrium—sarcoma	0.00174	0.0098	CbGeAlD
Trifluoperazine—Aplastic anaemia—Dactinomycin—sarcoma	0.00173	0.0103	CcSEcCtD
Trifluoperazine—Gait disturbance—Vincristine—sarcoma	0.00168	0.01	CcSEcCtD
Trifluoperazine—S100A4—lymph node—sarcoma	0.00162	0.00912	CbGeAlD
Trifluoperazine—CALM3—seminal vesicle—sarcoma	0.00157	0.00885	CbGeAlD
Trifluoperazine—SIGMAR1—myometrium—sarcoma	0.00156	0.00876	CbGeAlD
Trifluoperazine—HTR2A—endothelium—sarcoma	0.00145	0.00816	CbGeAlD
Trifluoperazine—SIGMAR1—seminal vesicle—sarcoma	0.00141	0.00791	CbGeAlD
Trifluoperazine—CALM2—myometrium—sarcoma	0.00137	0.0077	CbGeAlD
Trifluoperazine—TNNC1—lymph node—sarcoma	0.00136	0.00767	CbGeAlD
Trifluoperazine—CALM1—myometrium—sarcoma	0.00136	0.00766	CbGeAlD
Trifluoperazine—XDH—liver—sarcoma	0.00135	0.00762	CbGeAlD
Trifluoperazine—CALM3—smooth muscle tissue—sarcoma	0.00132	0.00741	CbGeAlD
Trifluoperazine—CALM2—embryo—sarcoma	0.00132	0.0074	CbGeAlD
Trifluoperazine—CALM1—embryo—sarcoma	0.00131	0.00737	CbGeAlD
Trifluoperazine—Urinary retention—Thiotepa—sarcoma	0.00128	0.0076	CcSEcCtD
Trifluoperazine—Cardiac arrest—Thiotepa—sarcoma	0.00128	0.0076	CcSEcCtD
Trifluoperazine—CALM2—seminal vesicle—sarcoma	0.00124	0.00695	CbGeAlD
Trifluoperazine—Anaphylactoid reaction—Mitoxantrone—sarcoma	0.0012	0.00713	CcSEcCtD
Trifluoperazine—HTR1A—hematopoietic system—sarcoma	0.00119	0.00672	CbGeAlD
Trifluoperazine—SIGMAR1—smooth muscle tissue—sarcoma	0.00118	0.00662	CbGeAlD
Trifluoperazine—CALM2—hematopoietic system—sarcoma	0.00117	0.00661	CbGeAlD
Trifluoperazine—CALM1—hematopoietic system—sarcoma	0.00117	0.00658	CbGeAlD
Trifluoperazine—Dysphagia—Dactinomycin—sarcoma	0.00115	0.00685	CcSEcCtD
Trifluoperazine—CALM3—cardiac atrium—sarcoma	0.00114	0.00639	CbGeAlD
Trifluoperazine—Urinary retention—Vincristine—sarcoma	0.00113	0.00674	CcSEcCtD
Trifluoperazine—Cardiac arrest—Vincristine—sarcoma	0.00113	0.00674	CcSEcCtD
Trifluoperazine—CALM2—connective tissue—sarcoma	0.00113	0.00636	CbGeAlD
Trifluoperazine—CALM3—uterus—sarcoma	0.00113	0.00636	CbGeAlD
Trifluoperazine—CALM1—connective tissue—sarcoma	0.00113	0.00633	CbGeAlD
Trifluoperazine—Pancytopenia—Thiotepa—sarcoma	0.0011	0.00656	CcSEcCtD
Trifluoperazine—ADRA1A—hematopoietic system—sarcoma	0.0011	0.0062	CbGeAlD
Trifluoperazine—Pancytopenia—Dactinomycin—sarcoma	0.0011	0.00651	CcSEcCtD
Trifluoperazine—Weight increased—Thiotepa—sarcoma	0.00106	0.00628	CcSEcCtD
Trifluoperazine—Ileus—Epirubicin—sarcoma	0.00105	0.00626	CcSEcCtD
Trifluoperazine—Muscular weakness—Vincristine—sarcoma	0.00105	0.00625	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Thiotepa—sarcoma	0.00105	0.00623	CcSEcCtD
Trifluoperazine—CALM2—smooth muscle tissue—sarcoma	0.00103	0.00582	CbGeAlD
Trifluoperazine—CALM1—smooth muscle tissue—sarcoma	0.00103	0.00579	CbGeAlD
Trifluoperazine—CALM2—skin of body—sarcoma	0.00102	0.00574	CbGeAlD
Trifluoperazine—CALM1—skin of body—sarcoma	0.00102	0.00572	CbGeAlD
Trifluoperazine—SIGMAR1—cardiac atrium—sarcoma	0.00101	0.00571	CbGeAlD
Trifluoperazine—Jaundice—Thiotepa—sarcoma	0.00101	0.006	CcSEcCtD
Trifluoperazine—SIGMAR1—uterus—sarcoma	0.00101	0.00568	CbGeAlD
Trifluoperazine—Ventricular arrhythmia—Epirubicin—sarcoma	0.00101	0.00599	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Etoposide—sarcoma	0.000998	0.00593	CcSEcCtD
Trifluoperazine—HRH1—myometrium—sarcoma	0.000993	0.00559	CbGeAlD
Trifluoperazine—CALM3—tendon—sarcoma	0.00099	0.00557	CbGeAlD
Trifluoperazine—Pancytopenia—Vincristine—sarcoma	0.000979	0.00582	CcSEcCtD
Trifluoperazine—Ileus—Doxorubicin—sarcoma	0.000975	0.00579	CcSEcCtD
Trifluoperazine—Agranulocytosis—Thiotepa—sarcoma	0.000967	0.00575	CcSEcCtD
Trifluoperazine—Agranulocytosis—Dactinomycin—sarcoma	0.00096	0.0057	CcSEcCtD
Trifluoperazine—CALM3—bone marrow—sarcoma	0.000959	0.00539	CbGeAlD
Trifluoperazine—Pancytopenia—Mitoxantrone—sarcoma	0.000953	0.00566	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Vincristine—sarcoma	0.000949	0.00564	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Vincristine—sarcoma	0.000941	0.00559	CcSEcCtD
Trifluoperazine—Ventricular arrhythmia—Doxorubicin—sarcoma	0.000933	0.00554	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Mitoxantrone—sarcoma	0.000925	0.00549	CcSEcCtD
Trifluoperazine—Glycosuria—Epirubicin—sarcoma	0.000921	0.00547	CcSEcCtD
Trifluoperazine—Cardiac arrest—Etoposide—sarcoma	0.000919	0.00546	CcSEcCtD
Trifluoperazine—Weight increased—Mitoxantrone—sarcoma	0.000914	0.00543	CcSEcCtD
Trifluoperazine—CYP1A2—hematopoietic system—sarcoma	0.000911	0.00512	CbGeAlD
Trifluoperazine—Hyperglycaemia—Mitoxantrone—sarcoma	0.000906	0.00538	CcSEcCtD
Trifluoperazine—Drowsiness—Mitoxantrone—sarcoma	0.000895	0.00532	CcSEcCtD
Trifluoperazine—Blood disorder—Epirubicin—sarcoma	0.000893	0.00531	CcSEcCtD
Trifluoperazine—CALM2—cardiac atrium—sarcoma	0.000892	0.00502	CbGeAlD
Trifluoperazine—CALM1—cardiac atrium—sarcoma	0.000888	0.00499	CbGeAlD
Trifluoperazine—CALM2—uterus—sarcoma	0.000887	0.00499	CbGeAlD
Trifluoperazine—Liver injury—Epirubicin—sarcoma	0.000887	0.00527	CcSEcCtD
Trifluoperazine—SIGMAR1—tendon—sarcoma	0.000885	0.00498	CbGeAlD
Trifluoperazine—CALM1—uterus—sarcoma	0.000883	0.00497	CbGeAlD
Trifluoperazine—Jaundice—Mitoxantrone—sarcoma	0.000872	0.00518	CcSEcCtD
Trifluoperazine—SIGMAR1—bone marrow—sarcoma	0.000857	0.00482	CbGeAlD
Trifluoperazine—HRH1—hematopoietic system—sarcoma	0.000853	0.0048	CbGeAlD
Trifluoperazine—Glycosuria—Doxorubicin—sarcoma	0.000852	0.00506	CcSEcCtD
Trifluoperazine—Amenorrhoea—Epirubicin—sarcoma	0.000849	0.00504	CcSEcCtD
Trifluoperazine—Agranulocytosis—Mitoxantrone—sarcoma	0.000835	0.00496	CcSEcCtD
Trifluoperazine—Dysphagia—Etoposide—sarcoma	0.000835	0.00496	CcSEcCtD
Trifluoperazine—CALM2—lymphoid tissue—sarcoma	0.000827	0.00465	CbGeAlD
Trifluoperazine—Blood disorder—Doxorubicin—sarcoma	0.000826	0.00491	CcSEcCtD
Trifluoperazine—CALM1—lymphoid tissue—sarcoma	0.000823	0.00463	CbGeAlD
Trifluoperazine—Bronchospasm—Etoposide—sarcoma	0.000821	0.00488	CcSEcCtD
Trifluoperazine—HRH1—connective tissue—sarcoma	0.000821	0.00462	CbGeAlD
Trifluoperazine—Liver injury—Doxorubicin—sarcoma	0.00082	0.00487	CcSEcCtD
Trifluoperazine—CALM3—testis—sarcoma	0.00082	0.00461	CbGeAlD
Trifluoperazine—Erythema—Thiotepa—sarcoma	0.00081	0.00481	CcSEcCtD
Trifluoperazine—Erythema—Dactinomycin—sarcoma	0.000804	0.00478	CcSEcCtD
Trifluoperazine—HTR2A—embryo—sarcoma	0.000798	0.00449	CbGeAlD
Trifluoperazine—Dyskinesia—Epirubicin—sarcoma	0.000794	0.00472	CcSEcCtD
Trifluoperazine—Pancytopenia—Etoposide—sarcoma	0.000793	0.00471	CcSEcCtD
Trifluoperazine—Nervousness—Thiotepa—sarcoma	0.000787	0.00467	CcSEcCtD
Trifluoperazine—Amenorrhoea—Doxorubicin—sarcoma	0.000786	0.00467	CcSEcCtD
Trifluoperazine—CALM2—tendon—sarcoma	0.000777	0.00437	CbGeAlD
Trifluoperazine—ADRA1A—lymphoid tissue—sarcoma	0.000776	0.00436	CbGeAlD
Trifluoperazine—CALM3—liver—sarcoma	0.000775	0.00436	CbGeAlD
Trifluoperazine—CALM1—tendon—sarcoma	0.000774	0.00435	CbGeAlD
Trifluoperazine—Gait disturbance—Epirubicin—sarcoma	0.000764	0.00454	CcSEcCtD
Trifluoperazine—Vision blurred—Thiotepa—sarcoma	0.000763	0.00453	CcSEcCtD
Trifluoperazine—CALM2—bone marrow—sarcoma	0.000753	0.00424	CbGeAlD
Trifluoperazine—HRH1—smooth muscle tissue—sarcoma	0.000751	0.00423	CbGeAlD
Trifluoperazine—CALM1—bone marrow—sarcoma	0.000749	0.00422	CbGeAlD
Trifluoperazine—Hepatocellular injury—Epirubicin—sarcoma	0.000746	0.00443	CcSEcCtD
Trifluoperazine—Agitation—Thiotepa—sarcoma	0.000744	0.00442	CcSEcCtD
Trifluoperazine—Dyskinesia—Doxorubicin—sarcoma	0.000735	0.00436	CcSEcCtD
Trifluoperazine—SIGMAR1—testis—sarcoma	0.000732	0.00412	CbGeAlD
Trifluoperazine—Jaundice—Etoposide—sarcoma	0.000726	0.00431	CcSEcCtD
Trifluoperazine—Leukopenia—Thiotepa—sarcoma	0.000725	0.00431	CcSEcCtD
Trifluoperazine—Leukopenia—Dactinomycin—sarcoma	0.00072	0.00427	CcSEcCtD
Trifluoperazine—HTR2A—hematopoietic system—sarcoma	0.000712	0.00401	CbGeAlD
Trifluoperazine—Gait disturbance—Doxorubicin—sarcoma	0.000707	0.0042	CcSEcCtD
Trifluoperazine—Cough—Thiotepa—sarcoma	0.000707	0.0042	CcSEcCtD
Trifluoperazine—Convulsion—Thiotepa—sarcoma	0.000702	0.00417	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Epirubicin—sarcoma	0.0007	0.00416	CcSEcCtD
Trifluoperazine—Erythema—Mitoxantrone—sarcoma	0.000699	0.00416	CcSEcCtD
Trifluoperazine—Agranulocytosis—Etoposide—sarcoma	0.000695	0.00413	CcSEcCtD
Trifluoperazine—SIGMAR1—liver—sarcoma	0.000692	0.0039	CbGeAlD
Trifluoperazine—Hepatocellular injury—Doxorubicin—sarcoma	0.00069	0.0041	CcSEcCtD
Trifluoperazine—HTR2A—connective tissue—sarcoma	0.000686	0.00386	CbGeAlD
Trifluoperazine—Agitation—Vincristine—sarcoma	0.00066	0.00392	CcSEcCtD
Trifluoperazine—Vision blurred—Mitoxantrone—sarcoma	0.000659	0.00392	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Doxorubicin—sarcoma	0.000648	0.00385	CcSEcCtD
Trifluoperazine—CALM2—testis—sarcoma	0.000644	0.00362	CbGeAlD
Trifluoperazine—Leukopenia—Vincristine—sarcoma	0.000643	0.00382	CcSEcCtD
Trifluoperazine—Skin disorder—Thiotepa—sarcoma	0.000642	0.00381	CcSEcCtD
Trifluoperazine—CALM1—testis—sarcoma	0.000641	0.0036	CbGeAlD
Trifluoperazine—Anorexia—Thiotepa—sarcoma	0.00063	0.00374	CcSEcCtD
Trifluoperazine—HTR2A—smooth muscle tissue—sarcoma	0.000627	0.00353	CbGeAlD
Trifluoperazine—Leukopenia—Mitoxantrone—sarcoma	0.000626	0.00372	CcSEcCtD
Trifluoperazine—Anorexia—Dactinomycin—sarcoma	0.000625	0.00372	CcSEcCtD
Trifluoperazine—Convulsion—Vincristine—sarcoma	0.000622	0.0037	CcSEcCtD
Trifluoperazine—Photosensitivity—Epirubicin—sarcoma	0.000617	0.00366	CcSEcCtD
Trifluoperazine—Cough—Mitoxantrone—sarcoma	0.00061	0.00363	CcSEcCtD
Trifluoperazine—CALM2—liver—sarcoma	0.000608	0.00342	CbGeAlD
Trifluoperazine—Convulsion—Mitoxantrone—sarcoma	0.000606	0.0036	CcSEcCtD
Trifluoperazine—CALM1—liver—sarcoma	0.000606	0.00341	CbGeAlD
Trifluoperazine—Eczema—Epirubicin—sarcoma	0.000603	0.00358	CcSEcCtD
Trifluoperazine—CALM3—lymph node—sarcoma	0.000594	0.00334	CbGeAlD
Trifluoperazine—DRD2—testis—sarcoma	0.000592	0.00333	CbGeAlD
Trifluoperazine—Somnolence—Thiotepa—sarcoma	0.000588	0.00349	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Vincristine—sarcoma	0.000586	0.00348	CcSEcCtD
Trifluoperazine—Increased appetite—Epirubicin—sarcoma	0.000576	0.00342	CcSEcCtD
Trifluoperazine—Decreased appetite—Thiotepa—sarcoma	0.000575	0.00341	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Epirubicin—sarcoma	0.000574	0.00341	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Mitoxantrone—sarcoma	0.000571	0.00339	CcSEcCtD
Trifluoperazine—ADRA1A—liver—sarcoma	0.000571	0.00321	CbGeAlD
Trifluoperazine—Photosensitivity—Doxorubicin—sarcoma	0.000571	0.00339	CcSEcCtD
Trifluoperazine—Decreased appetite—Dactinomycin—sarcoma	0.00057	0.00339	CcSEcCtD
Trifluoperazine—Fatigue—Thiotepa—sarcoma	0.00057	0.00339	CcSEcCtD
Trifluoperazine—Fatigue—Dactinomycin—sarcoma	0.000566	0.00336	CcSEcCtD
Trifluoperazine—Constipation—Thiotepa—sarcoma	0.000565	0.00336	CcSEcCtD
Trifluoperazine—HRH1—tendon—sarcoma	0.000564	0.00317	CbGeAlD
Trifluoperazine—Anaphylactoid reaction—Epirubicin—sarcoma	0.00056	0.00332	CcSEcCtD
Trifluoperazine—Muscle spasms—Etoposide—sarcoma	0.000559	0.00332	CcSEcCtD
Trifluoperazine—Anorexia—Vincristine—sarcoma	0.000559	0.00332	CcSEcCtD
Trifluoperazine—Eczema—Doxorubicin—sarcoma	0.000558	0.00331	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Epirubicin—sarcoma	0.000555	0.0033	CcSEcCtD
Trifluoperazine—Skin disorder—Mitoxantrone—sarcoma	0.000554	0.00329	CcSEcCtD
Trifluoperazine—Hypotension—Vincristine—sarcoma	0.000548	0.00325	CcSEcCtD
Trifluoperazine—Anorexia—Mitoxantrone—sarcoma	0.000544	0.00323	CcSEcCtD
Trifluoperazine—ABCB1—myometrium—sarcoma	0.000544	0.00306	CbGeAlD
Trifluoperazine—Hypotension—Mitoxantrone—sarcoma	0.000533	0.00317	CcSEcCtD
Trifluoperazine—Increased appetite—Doxorubicin—sarcoma	0.000533	0.00317	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Doxorubicin—sarcoma	0.000531	0.00315	CcSEcCtD
Trifluoperazine—SIGMAR1—lymph node—sarcoma	0.000531	0.00299	CbGeAlD
Trifluoperazine—Insomnia—Vincristine—sarcoma	0.00053	0.00315	CcSEcCtD
Trifluoperazine—Urticaria—Thiotepa—sarcoma	0.000525	0.00312	CcSEcCtD
Trifluoperazine—ABCB1—embryo—sarcoma	0.000523	0.00294	CbGeAlD
Trifluoperazine—Body temperature increased—Thiotepa—sarcoma	0.000523	0.0031	CcSEcCtD
Trifluoperazine—Leukopenia—Etoposide—sarcoma	0.000521	0.00309	CcSEcCtD
Trifluoperazine—Body temperature increased—Dactinomycin—sarcoma	0.000519	0.00308	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000518	0.00308	CcSEcCtD
Trifluoperazine—Cardiac arrest—Epirubicin—sarcoma	0.000515	0.00306	CcSEcCtD
Trifluoperazine—Hypoglycaemia—Doxorubicin—sarcoma	0.000513	0.00305	CcSEcCtD
Trifluoperazine—Decreased appetite—Vincristine—sarcoma	0.00051	0.00303	CcSEcCtD
Trifluoperazine—Dyspnoea—Mitoxantrone—sarcoma	0.000509	0.00302	CcSEcCtD
Trifluoperazine—Cough—Etoposide—sarcoma	0.000508	0.00302	CcSEcCtD
Trifluoperazine—Somnolence—Mitoxantrone—sarcoma	0.000507	0.00302	CcSEcCtD
Trifluoperazine—Fatigue—Vincristine—sarcoma	0.000505	0.003	CcSEcCtD
Trifluoperazine—Convulsion—Etoposide—sarcoma	0.000504	0.00299	CcSEcCtD
Trifluoperazine—Constipation—Vincristine—sarcoma	0.000501	0.00298	CcSEcCtD
Trifluoperazine—Decreased appetite—Mitoxantrone—sarcoma	0.000496	0.00295	CcSEcCtD
Trifluoperazine—Fatigue—Mitoxantrone—sarcoma	0.000492	0.00292	CcSEcCtD
Trifluoperazine—ABCB1—seminal vesicle—sarcoma	0.000491	0.00276	CbGeAlD
Trifluoperazine—Constipation—Mitoxantrone—sarcoma	0.000488	0.0029	CcSEcCtD
Trifluoperazine—Hypersensitivity—Thiotepa—sarcoma	0.000487	0.00289	CcSEcCtD
Trifluoperazine—Hypersensitivity—Dactinomycin—sarcoma	0.000483	0.00287	CcSEcCtD
Trifluoperazine—Muscular weakness—Epirubicin—sarcoma	0.000478	0.00284	CcSEcCtD
Trifluoperazine—Cardiac arrest—Doxorubicin—sarcoma	0.000476	0.00283	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Etoposide—sarcoma	0.000475	0.00282	CcSEcCtD
Trifluoperazine—Asthenia—Thiotepa—sarcoma	0.000474	0.00282	CcSEcCtD
Trifluoperazine—CYP1A2—liver—sarcoma	0.000472	0.00265	CbGeAlD
Trifluoperazine—HTR2A—tendon—sarcoma	0.000471	0.00265	CbGeAlD
Trifluoperazine—Asthenia—Dactinomycin—sarcoma	0.000471	0.0028	CcSEcCtD
Trifluoperazine—Asthma—Epirubicin—sarcoma	0.000468	0.00278	CcSEcCtD
Trifluoperazine—Dysphagia—Epirubicin—sarcoma	0.000468	0.00278	CcSEcCtD
Trifluoperazine—Pruritus—Thiotepa—sarcoma	0.000468	0.00278	CcSEcCtD
Trifluoperazine—HRH1—testis—sarcoma	0.000467	0.00263	CbGeAlD
Trifluoperazine—ABCB1—hematopoietic system—sarcoma	0.000467	0.00263	CbGeAlD
Trifluoperazine—CALM2—lymph node—sarcoma	0.000467	0.00262	CbGeAlD
Trifluoperazine—CALM1—lymph node—sarcoma	0.000464	0.00261	CbGeAlD
Trifluoperazine—Eosinophilia—Epirubicin—sarcoma	0.000463	0.00275	CcSEcCtD
Trifluoperazine—Body temperature increased—Vincristine—sarcoma	0.000463	0.00275	CcSEcCtD
Trifluoperazine—Skin disorder—Etoposide—sarcoma	0.000461	0.00274	CcSEcCtD
Trifluoperazine—Urticaria—Mitoxantrone—sarcoma	0.000454	0.00269	CcSEcCtD
Trifluoperazine—Anorexia—Etoposide—sarcoma	0.000453	0.00269	CcSEcCtD
Trifluoperazine—Body temperature increased—Mitoxantrone—sarcoma	0.000451	0.00268	CcSEcCtD
Trifluoperazine—Pancytopenia—Epirubicin—sarcoma	0.000445	0.00264	CcSEcCtD
Trifluoperazine—Hypotension—Etoposide—sarcoma	0.000444	0.00264	CcSEcCtD
Trifluoperazine—Muscular weakness—Doxorubicin—sarcoma	0.000442	0.00263	CcSEcCtD
Trifluoperazine—Dizziness—Thiotepa—sarcoma	0.000437	0.0026	CcSEcCtD
Trifluoperazine—Asthma—Doxorubicin—sarcoma	0.000433	0.00257	CcSEcCtD
Trifluoperazine—Dysphagia—Doxorubicin—sarcoma	0.000433	0.00257	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vincristine—sarcoma	0.000432	0.00257	CcSEcCtD
Trifluoperazine—Eosinophilia—Doxorubicin—sarcoma	0.000429	0.00255	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Epirubicin—sarcoma	0.000427	0.00254	CcSEcCtD
Trifluoperazine—Weight increased—Epirubicin—sarcoma	0.000426	0.00253	CcSEcCtD
Trifluoperazine—Dyspnoea—Etoposide—sarcoma	0.000423	0.00252	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Epirubicin—sarcoma	0.000422	0.00251	CcSEcCtD
Trifluoperazine—Somnolence—Etoposide—sarcoma	0.000422	0.00251	CcSEcCtD
Trifluoperazine—Hypersensitivity—Mitoxantrone—sarcoma	0.000421	0.0025	CcSEcCtD
Trifluoperazine—Asthenia—Vincristine—sarcoma	0.000421	0.0025	CcSEcCtD
Trifluoperazine—Drowsiness—Epirubicin—sarcoma	0.000417	0.00248	CcSEcCtD
Trifluoperazine—Rash—Thiotepa—sarcoma	0.000417	0.00248	CcSEcCtD
Trifluoperazine—Dermatitis—Thiotepa—sarcoma	0.000416	0.00247	CcSEcCtD
Trifluoperazine—Headache—Thiotepa—sarcoma	0.000414	0.00246	CcSEcCtD
Trifluoperazine—Rash—Dactinomycin—sarcoma	0.000414	0.00246	CcSEcCtD
Trifluoperazine—Decreased appetite—Etoposide—sarcoma	0.000413	0.00245	CcSEcCtD
Trifluoperazine—Pancytopenia—Doxorubicin—sarcoma	0.000411	0.00244	CcSEcCtD
Trifluoperazine—Asthenia—Mitoxantrone—sarcoma	0.00041	0.00243	CcSEcCtD
Trifluoperazine—Fatigue—Etoposide—sarcoma	0.000409	0.00243	CcSEcCtD
Trifluoperazine—Jaundice—Epirubicin—sarcoma	0.000407	0.00242	CcSEcCtD
Trifluoperazine—Constipation—Etoposide—sarcoma	0.000406	0.00241	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Doxorubicin—sarcoma	0.000395	0.00235	CcSEcCtD
Trifluoperazine—Weight increased—Doxorubicin—sarcoma	0.000394	0.00234	CcSEcCtD
Trifluoperazine—Nausea—Thiotepa—sarcoma	0.000393	0.00233	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Doxorubicin—sarcoma	0.000391	0.00232	CcSEcCtD
Trifluoperazine—HTR2A—testis—sarcoma	0.00039	0.0022	CbGeAlD
Trifluoperazine—Nausea—Dactinomycin—sarcoma	0.00039	0.00232	CcSEcCtD
Trifluoperazine—Agranulocytosis—Epirubicin—sarcoma	0.000389	0.00231	CcSEcCtD
Trifluoperazine—Dizziness—Vincristine—sarcoma	0.000388	0.0023	CcSEcCtD
Trifluoperazine—Drowsiness—Doxorubicin—sarcoma	0.000386	0.00229	CcSEcCtD
Trifluoperazine—Urticaria—Etoposide—sarcoma	0.000377	0.00224	CcSEcCtD
Trifluoperazine—Jaundice—Doxorubicin—sarcoma	0.000376	0.00224	CcSEcCtD
Trifluoperazine—Body temperature increased—Etoposide—sarcoma	0.000375	0.00223	CcSEcCtD
Trifluoperazine—Rash—Vincristine—sarcoma	0.00037	0.0022	CcSEcCtD
Trifluoperazine—Dermatitis—Vincristine—sarcoma	0.000369	0.00219	CcSEcCtD
Trifluoperazine—Oedema peripheral—Epirubicin—sarcoma	0.000369	0.00219	CcSEcCtD
Trifluoperazine—HTR2A—liver—sarcoma	0.000369	0.00208	CbGeAlD
Trifluoperazine—Headache—Vincristine—sarcoma	0.000367	0.00218	CcSEcCtD
Trifluoperazine—Agranulocytosis—Doxorubicin—sarcoma	0.00036	0.00214	CcSEcCtD
Trifluoperazine—Rash—Mitoxantrone—sarcoma	0.00036	0.00214	CcSEcCtD
Trifluoperazine—Dermatitis—Mitoxantrone—sarcoma	0.00036	0.00214	CcSEcCtD
Trifluoperazine—Headache—Mitoxantrone—sarcoma	0.000358	0.00212	CcSEcCtD
Trifluoperazine—ABCB1—uterus—sarcoma	0.000353	0.00198	CbGeAlD
Trifluoperazine—Hypersensitivity—Etoposide—sarcoma	0.00035	0.00208	CcSEcCtD
Trifluoperazine—Nausea—Vincristine—sarcoma	0.000348	0.00207	CcSEcCtD
Trifluoperazine—Oedema peripheral—Doxorubicin—sarcoma	0.000341	0.00203	CcSEcCtD
Trifluoperazine—Asthenia—Etoposide—sarcoma	0.000341	0.00202	CcSEcCtD
Trifluoperazine—Nausea—Mitoxantrone—sarcoma	0.000339	0.00201	CcSEcCtD
Trifluoperazine—HRH1—lymph node—sarcoma	0.000339	0.00191	CbGeAlD
Trifluoperazine—Pruritus—Etoposide—sarcoma	0.000336	0.002	CcSEcCtD
Trifluoperazine—ABCB1—lymphoid tissue—sarcoma	0.000329	0.00185	CbGeAlD
Trifluoperazine—Erythema—Epirubicin—sarcoma	0.000326	0.00194	CcSEcCtD
Trifluoperazine—Nervousness—Epirubicin—sarcoma	0.000317	0.00188	CcSEcCtD
Trifluoperazine—Dizziness—Etoposide—sarcoma	0.000314	0.00187	CcSEcCtD
Trifluoperazine—Muscle spasms—Epirubicin—sarcoma	0.000314	0.00186	CcSEcCtD
Trifluoperazine—Vision blurred—Epirubicin—sarcoma	0.000307	0.00183	CcSEcCtD
Trifluoperazine—Erythema—Doxorubicin—sarcoma	0.000302	0.00179	CcSEcCtD
Trifluoperazine—Agitation—Epirubicin—sarcoma	0.0003	0.00178	CcSEcCtD
Trifluoperazine—Rash—Etoposide—sarcoma	0.000299	0.00178	CcSEcCtD
Trifluoperazine—ABCB1—bone marrow—sarcoma	0.000299	0.00168	CbGeAlD
Trifluoperazine—Dermatitis—Etoposide—sarcoma	0.000299	0.00178	CcSEcCtD
Trifluoperazine—Headache—Etoposide—sarcoma	0.000297	0.00177	CcSEcCtD
Trifluoperazine—Nervousness—Doxorubicin—sarcoma	0.000293	0.00174	CcSEcCtD
Trifluoperazine—Leukopenia—Epirubicin—sarcoma	0.000292	0.00173	CcSEcCtD
Trifluoperazine—Muscle spasms—Doxorubicin—sarcoma	0.00029	0.00172	CcSEcCtD
Trifluoperazine—Cough—Epirubicin—sarcoma	0.000285	0.00169	CcSEcCtD
Trifluoperazine—Vision blurred—Doxorubicin—sarcoma	0.000284	0.00169	CcSEcCtD
Trifluoperazine—Convulsion—Epirubicin—sarcoma	0.000283	0.00168	CcSEcCtD
Trifluoperazine—Nausea—Etoposide—sarcoma	0.000282	0.00168	CcSEcCtD
Trifluoperazine—Agitation—Doxorubicin—sarcoma	0.000277	0.00165	CcSEcCtD
Trifluoperazine—Dry mouth—Epirubicin—sarcoma	0.000272	0.00161	CcSEcCtD
Trifluoperazine—Leukopenia—Doxorubicin—sarcoma	0.00027	0.0016	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Epirubicin—sarcoma	0.000266	0.00158	CcSEcCtD
Trifluoperazine—Cough—Doxorubicin—sarcoma	0.000263	0.00156	CcSEcCtD
Trifluoperazine—Convulsion—Doxorubicin—sarcoma	0.000261	0.00155	CcSEcCtD
Trifluoperazine—Skin disorder—Epirubicin—sarcoma	0.000259	0.00154	CcSEcCtD
Trifluoperazine—ABCB1—testis—sarcoma	0.000256	0.00144	CbGeAlD
Trifluoperazine—Anorexia—Epirubicin—sarcoma	0.000254	0.00151	CcSEcCtD
Trifluoperazine—Dry mouth—Doxorubicin—sarcoma	0.000251	0.00149	CcSEcCtD
Trifluoperazine—Hypotension—Epirubicin—sarcoma	0.000249	0.00148	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Doxorubicin—sarcoma	0.000246	0.00146	CcSEcCtD
Trifluoperazine—ABCB1—liver—sarcoma	0.000242	0.00136	CbGeAlD
Trifluoperazine—Insomnia—Epirubicin—sarcoma	0.000241	0.00143	CcSEcCtD
Trifluoperazine—Skin disorder—Doxorubicin—sarcoma	0.000239	0.00142	CcSEcCtD
Trifluoperazine—Dyspnoea—Epirubicin—sarcoma	0.000237	0.00141	CcSEcCtD
Trifluoperazine—Somnolence—Epirubicin—sarcoma	0.000237	0.00141	CcSEcCtD
Trifluoperazine—Anorexia—Doxorubicin—sarcoma	0.000235	0.00139	CcSEcCtD
Trifluoperazine—Decreased appetite—Epirubicin—sarcoma	0.000231	0.00137	CcSEcCtD
Trifluoperazine—Hypotension—Doxorubicin—sarcoma	0.00023	0.00137	CcSEcCtD
Trifluoperazine—Fatigue—Epirubicin—sarcoma	0.000229	0.00136	CcSEcCtD
Trifluoperazine—Constipation—Epirubicin—sarcoma	0.000228	0.00135	CcSEcCtD
Trifluoperazine—Insomnia—Doxorubicin—sarcoma	0.000223	0.00132	CcSEcCtD
Trifluoperazine—Dyspnoea—Doxorubicin—sarcoma	0.00022	0.0013	CcSEcCtD
Trifluoperazine—Somnolence—Doxorubicin—sarcoma	0.000219	0.0013	CcSEcCtD
Trifluoperazine—Decreased appetite—Doxorubicin—sarcoma	0.000214	0.00127	CcSEcCtD
Trifluoperazine—Fatigue—Doxorubicin—sarcoma	0.000212	0.00126	CcSEcCtD
Trifluoperazine—Urticaria—Epirubicin—sarcoma	0.000211	0.00126	CcSEcCtD
Trifluoperazine—Constipation—Doxorubicin—sarcoma	0.000211	0.00125	CcSEcCtD
Trifluoperazine—Body temperature increased—Epirubicin—sarcoma	0.00021	0.00125	CcSEcCtD
Trifluoperazine—Hypersensitivity—Epirubicin—sarcoma	0.000196	0.00117	CcSEcCtD
Trifluoperazine—Urticaria—Doxorubicin—sarcoma	0.000196	0.00116	CcSEcCtD
Trifluoperazine—Body temperature increased—Doxorubicin—sarcoma	0.000195	0.00116	CcSEcCtD
Trifluoperazine—Asthenia—Epirubicin—sarcoma	0.000191	0.00113	CcSEcCtD
Trifluoperazine—Pruritus—Epirubicin—sarcoma	0.000188	0.00112	CcSEcCtD
Trifluoperazine—ABCB1—lymph node—sarcoma	0.000185	0.00104	CbGeAlD
Trifluoperazine—Hypersensitivity—Doxorubicin—sarcoma	0.000181	0.00108	CcSEcCtD
Trifluoperazine—Asthenia—Doxorubicin—sarcoma	0.000177	0.00105	CcSEcCtD
Trifluoperazine—Dizziness—Epirubicin—sarcoma	0.000176	0.00105	CcSEcCtD
Trifluoperazine—Pruritus—Doxorubicin—sarcoma	0.000174	0.00104	CcSEcCtD
Trifluoperazine—Rash—Epirubicin—sarcoma	0.000168	0.000997	CcSEcCtD
Trifluoperazine—Dermatitis—Epirubicin—sarcoma	0.000168	0.000996	CcSEcCtD
Trifluoperazine—Headache—Epirubicin—sarcoma	0.000167	0.000991	CcSEcCtD
Trifluoperazine—Dizziness—Doxorubicin—sarcoma	0.000163	0.000968	CcSEcCtD
Trifluoperazine—Nausea—Epirubicin—sarcoma	0.000158	0.000939	CcSEcCtD
Trifluoperazine—Rash—Doxorubicin—sarcoma	0.000155	0.000923	CcSEcCtD
Trifluoperazine—Dermatitis—Doxorubicin—sarcoma	0.000155	0.000922	CcSEcCtD
Trifluoperazine—Headache—Doxorubicin—sarcoma	0.000154	0.000917	CcSEcCtD
Trifluoperazine—Nausea—Doxorubicin—sarcoma	0.000146	0.000869	CcSEcCtD
Trifluoperazine—HTR2A—Signaling Pathways—KIT—sarcoma	1.83e-05	6.97e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—NRAS—sarcoma	1.83e-05	6.97e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KIT—sarcoma	1.82e-05	6.95e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—NRAS—sarcoma	1.82e-05	6.95e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—KRAS—sarcoma	1.82e-05	6.94e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—KRAS—sarcoma	1.81e-05	6.91e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL2—sarcoma	1.81e-05	6.89e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KIT—sarcoma	1.79e-05	6.84e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—NRAS—sarcoma	1.79e-05	6.84e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KIT—sarcoma	1.79e-05	6.82e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—NRAS—sarcoma	1.79e-05	6.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—MDM2—sarcoma	1.79e-05	6.82e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—MDM2—sarcoma	1.79e-05	6.82e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CREB1—sarcoma	1.77e-05	6.74e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—SRC—sarcoma	1.76e-05	6.69e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL2—sarcoma	1.75e-05	6.67e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL2—sarcoma	1.75e-05	6.67e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—HRAS—sarcoma	1.74e-05	6.64e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CREB1—sarcoma	1.74e-05	6.63e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CREB1—sarcoma	1.74e-05	6.62e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—VEGFA—sarcoma	1.71e-05	6.52e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CREB1—sarcoma	1.71e-05	6.51e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MDM2—sarcoma	1.71e-05	6.51e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CREB1—sarcoma	1.7e-05	6.49e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—EGFR—sarcoma	1.69e-05	6.45e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—NRAS—sarcoma	1.69e-05	6.44e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—HRAS—sarcoma	1.68e-05	6.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—HRAS—sarcoma	1.68e-05	6.42e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Adaptive Immune System—HRAS—sarcoma	1.67e-05	6.37e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MDM2—sarcoma	1.67e-05	6.35e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—EGFR—sarcoma	1.67e-05	6.35e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—EGFR—sarcoma	1.66e-05	6.34e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MDM2—sarcoma	1.66e-05	6.32e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL2—sarcoma	1.65e-05	6.3e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MDM2—sarcoma	1.65e-05	6.29e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MDM2—sarcoma	1.65e-05	6.29e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KDR—sarcoma	1.65e-05	6.28e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—EGFR—sarcoma	1.64e-05	6.23e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—EGFR—sarcoma	1.63e-05	6.22e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Adaptive Immune System—HRAS—sarcoma	1.62e-05	6.17e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Adaptive Immune System—HRAS—sarcoma	1.62e-05	6.17e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—JUN—sarcoma	1.61e-05	6.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—KRAS—sarcoma	1.6e-05	6.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL2—sarcoma	1.6e-05	6.09e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL2—sarcoma	1.6e-05	6.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—CTNNB1—sarcoma	1.59e-05	6.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KDR—sarcoma	1.59e-05	6.07e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KDR—sarcoma	1.59e-05	6.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—KRAS—sarcoma	1.57e-05	6e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MYC—sarcoma	1.57e-05	6e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—KRAS—sarcoma	1.57e-05	5.98e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—JUN—sarcoma	1.55e-05	5.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—JUN—sarcoma	1.55e-05	5.92e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—HRAS—sarcoma	1.55e-05	5.9e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—KRAS—sarcoma	1.54e-05	5.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—CTNNB1—sarcoma	1.54e-05	5.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—CTNNB1—sarcoma	1.54e-05	5.88e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—KRAS—sarcoma	1.54e-05	5.87e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—HRAS—sarcoma	1.54e-05	5.87e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—EGFR—sarcoma	1.54e-05	5.86e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KIT—sarcoma	1.52e-05	5.78e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—NRAS—sarcoma	1.52e-05	5.78e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL2—sarcoma	1.49e-05	5.68e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL2—sarcoma	1.48e-05	5.65e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—CTNNB1—sarcoma	1.47e-05	5.61e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KIT—sarcoma	1.47e-05	5.6e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KIT—sarcoma	1.47e-05	5.6e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—NRAS—sarcoma	1.47e-05	5.6e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—NRAS—sarcoma	1.47e-05	5.6e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MDM2—sarcoma	1.46e-05	5.58e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—KRAS—sarcoma	1.45e-05	5.54e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CCND1—sarcoma	1.45e-05	5.53e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—JUN—sarcoma	1.45e-05	5.52e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CREB1—sarcoma	1.44e-05	5.51e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CCND1—sarcoma	1.44e-05	5.5e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—SRC—sarcoma	1.44e-05	5.49e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—JUN—sarcoma	1.44e-05	5.49e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MDM2—sarcoma	1.44e-05	5.49e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—CTNNB1—sarcoma	1.44e-05	5.48e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MDM2—sarcoma	1.44e-05	5.48e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—CTNNB1—sarcoma	1.43e-05	5.45e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—CTNNB1—sarcoma	1.42e-05	5.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—CTNNB1—sarcoma	1.42e-05	5.43e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MDM2—sarcoma	1.41e-05	5.39e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MDM2—sarcoma	1.41e-05	5.37e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CREB1—sarcoma	1.4e-05	5.33e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CREB1—sarcoma	1.4e-05	5.33e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—SRC—sarcoma	1.39e-05	5.31e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—SRC—sarcoma	1.39e-05	5.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—NRAS—sarcoma	1.39e-05	5.29e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—EGFR—sarcoma	1.38e-05	5.27e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—HRAS—sarcoma	1.36e-05	5.18e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—NRAS—sarcoma	1.34e-05	5.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—NRAS—sarcoma	1.34e-05	5.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—EGFR—sarcoma	1.34e-05	5.1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—EGFR—sarcoma	1.34e-05	5.1e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—HRAS—sarcoma	1.34e-05	5.1e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—HRAS—sarcoma	1.33e-05	5.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—SRC—sarcoma	1.33e-05	5.07e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—HRAS—sarcoma	1.31e-05	5.01e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—HRAS—sarcoma	1.31e-05	4.99e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL2—sarcoma	1.31e-05	4.98e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—KRAS—sarcoma	1.31e-05	4.98e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—SRC—sarcoma	1.3e-05	4.95e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—SRC—sarcoma	1.29e-05	4.93e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TP53—sarcoma	1.29e-05	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—SRC—sarcoma	1.29e-05	4.91e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—SRC—sarcoma	1.29e-05	4.91e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL2—sarcoma	1.29e-05	4.9e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL2—sarcoma	1.28e-05	4.89e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—NRAS—sarcoma	1.28e-05	4.88e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CCND1—sarcoma	1.27e-05	4.86e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—JUN—sarcoma	1.27e-05	4.85e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—VEGFA—sarcoma	1.27e-05	4.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—KRAS—sarcoma	1.26e-05	4.82e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—KRAS—sarcoma	1.26e-05	4.82e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—EGFR—sarcoma	1.26e-05	4.82e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL2—sarcoma	1.26e-05	4.81e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—CTNNB1—sarcoma	1.26e-05	4.81e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL2—sarcoma	1.26e-05	4.8e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—VEGFA—sarcoma	1.26e-05	4.8e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CCND1—sarcoma	1.25e-05	4.78e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—JUN—sarcoma	1.25e-05	4.77e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CCND1—sarcoma	1.25e-05	4.77e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—NRAS—sarcoma	1.25e-05	4.76e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—JUN—sarcoma	1.25e-05	4.76e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—NRAS—sarcoma	1.24e-05	4.74e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—CTNNB1—sarcoma	1.24e-05	4.73e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—CTNNB1—sarcoma	1.24e-05	4.72e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—NRAS—sarcoma	1.24e-05	4.72e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—NRAS—sarcoma	1.24e-05	4.72e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—HRAS—sarcoma	1.24e-05	4.71e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CCND1—sarcoma	1.23e-05	4.69e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—JUN—sarcoma	1.23e-05	4.68e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CCND1—sarcoma	1.23e-05	4.68e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—JUN—sarcoma	1.23e-05	4.67e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—EGFR—sarcoma	1.22e-05	4.66e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—EGFR—sarcoma	1.22e-05	4.66e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CTNNB1—sarcoma	1.22e-05	4.65e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CTNNB1—sarcoma	1.22e-05	4.64e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MDM2—sarcoma	1.19e-05	4.56e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KRAS—sarcoma	1.19e-05	4.55e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—sarcoma	1.19e-05	4.55e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—sarcoma	1.17e-05	4.45e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—sarcoma	1.16e-05	4.44e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—sarcoma	1.16e-05	4.42e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MDM2—sarcoma	1.16e-05	4.41e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MDM2—sarcoma	1.16e-05	4.41e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KRAS—sarcoma	1.15e-05	4.4e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KRAS—sarcoma	1.15e-05	4.4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—sarcoma	1.15e-05	4.4e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—sarcoma	1.15e-05	4.4e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SRC—sarcoma	1.14e-05	4.35e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—sarcoma	1.14e-05	4.34e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—sarcoma	1.13e-05	4.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—sarcoma	1.13e-05	4.3e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—sarcoma	1.13e-05	4.3e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SRC—sarcoma	1.12e-05	4.28e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SRC—sarcoma	1.12e-05	4.27e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—sarcoma	1.11e-05	4.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—HRAS—sarcoma	1.11e-05	4.23e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SRC—sarcoma	1.1e-05	4.2e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KRAS—sarcoma	1.1e-05	4.2e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SRC—sarcoma	1.1e-05	4.19e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NRAS—sarcoma	1.1e-05	4.18e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—sarcoma	1.09e-05	4.17e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—sarcoma	1.09e-05	4.16e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NRAS—sarcoma	1.08e-05	4.12e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NRAS—sarcoma	1.08e-05	4.11e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KRAS—sarcoma	1.08e-05	4.1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—HRAS—sarcoma	1.07e-05	4.09e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—HRAS—sarcoma	1.07e-05	4.09e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—sarcoma	1.07e-05	4.09e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—sarcoma	1.07e-05	4.08e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KRAS—sarcoma	1.07e-05	4.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL2—sarcoma	1.07e-05	4.07e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KRAS—sarcoma	1.07e-05	4.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KRAS—sarcoma	1.07e-05	4.06e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NRAS—sarcoma	1.06e-05	4.04e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NRAS—sarcoma	1.06e-05	4.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—sarcoma	1.04e-05	3.97e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—JUN—sarcoma	1.04e-05	3.96e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL2—sarcoma	1.03e-05	3.94e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL2—sarcoma	1.03e-05	3.94e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CTNNB1—sarcoma	1.03e-05	3.93e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—sarcoma	1.02e-05	3.9e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HRAS—sarcoma	1.01e-05	3.87e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—sarcoma	1.01e-05	3.84e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—sarcoma	1.01e-05	3.84e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—sarcoma	1.01e-05	3.83e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—JUN—sarcoma	1e-05	3.83e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—JUN—sarcoma	1e-05	3.83e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—sarcoma	1e-05	3.83e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—sarcoma	1e-05	3.81e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CTNNB1—sarcoma	9.97e-06	3.8e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CTNNB1—sarcoma	9.97e-06	3.8e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—sarcoma	9.88e-06	3.76e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—sarcoma	9.85e-06	3.75e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—sarcoma	9.84e-06	3.75e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—sarcoma	9.82e-06	3.74e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HRAS—sarcoma	9.81e-06	3.74e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HRAS—sarcoma	9.81e-06	3.74e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—sarcoma	9.66e-06	3.68e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—sarcoma	9.63e-06	3.67e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—sarcoma	9.56e-06	3.65e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—sarcoma	9.51e-06	3.63e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KRAS—sarcoma	9.44e-06	3.6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HRAS—sarcoma	9.36e-06	3.57e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SRC—sarcoma	9.32e-06	3.55e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KRAS—sarcoma	9.29e-06	3.54e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KRAS—sarcoma	9.27e-06	3.54e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HRAS—sarcoma	9.14e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KRAS—sarcoma	9.12e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KRAS—sarcoma	9.1e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HRAS—sarcoma	9.1e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—sarcoma	9.07e-06	3.46e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HRAS—sarcoma	9.06e-06	3.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HRAS—sarcoma	9.06e-06	3.45e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SRC—sarcoma	9.01e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SRC—sarcoma	9.01e-06	3.44e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NRAS—sarcoma	8.96e-06	3.42e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—sarcoma	8.78e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—sarcoma	8.78e-06	3.35e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NRAS—sarcoma	8.67e-06	3.31e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NRAS—sarcoma	8.67e-06	3.31e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—sarcoma	8.39e-06	3.2e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—sarcoma	8.35e-06	3.18e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—sarcoma	8.26e-06	3.15e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—sarcoma	8.24e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—sarcoma	8.17e-06	3.11e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—sarcoma	8.11e-06	3.09e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—sarcoma	8.09e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—sarcoma	8.08e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—sarcoma	8.08e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HRAS—sarcoma	8.03e-06	3.06e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—sarcoma	7.9e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—sarcoma	7.9e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HRAS—sarcoma	7.9e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HRAS—sarcoma	7.88e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HRAS—sarcoma	7.76e-06	2.96e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HRAS—sarcoma	7.73e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KRAS—sarcoma	7.71e-06	2.94e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KRAS—sarcoma	7.46e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KRAS—sarcoma	7.46e-06	2.85e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—sarcoma	6.86e-06	2.61e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—sarcoma	6.63e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—sarcoma	6.63e-06	2.53e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HRAS—sarcoma	6.56e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HRAS—sarcoma	6.34e-06	2.42e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HRAS—sarcoma	6.34e-06	2.42e-05	CbGpPWpGaD
